BioNTech executive Sierk Poetting sold shares valued at seven million dollars one day after the company's founders, Ugur Sahin and Özlem Türeci, unexpectedly announced their intention to leave the company by the end of the year. The timing of the share sale has drawn attention, particularly because it came immediately after the founders’ departure announcement, which caused the stock price of BioNTech to plummet by as much as 20 percent at one point. This situation has raised concerns among investors and analysts regarding the stability and future direction of the company.

The company attributed Poetting’s decision to sell his shares to a previously submitted intention to do so, which was lodged with the stock market authority back in November 2025. Despite the timing being described as unfortunate, it appears Poetting's decision to sell was part of a planned move rather than a reaction to the changing circumstances around the company due to the founders’ announcement. Such a significant sale raises questions about insider trading and the ethical considerations surrounding executive stock sales, especially in light of the company's recent developments.

As BioNTech is known for its pivotal role in creating one of the first COVID-19 vaccines in collaboration with Pfizer, leadership changes and executive stock sales draw keen interest from the market. The departure of Sahin and Türeci, who co-founded BioNTech and led its innovations, could potentially impact investor confidence and the company's future projects, especially as they plan to focus their efforts on establishing a new venture in medical research. Investors will be closely watching how the new leadership and strategic direction of BioNTech will unfold in the coming months as they navigate these changes.